揭开固体瘤中的免疫疗法抵抗:解码机制和绘制未来治疗景观的图表
Huan Wang1, Jindong Xie1, Na Li1
1State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
药物耐药性限制了免疫检查点抑制剂在固体瘤中的有效性. 本综述探讨了耐药性机制,组合疗法和纳米尺度的交付,以克服这些挑战并改善癌症治疗.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 纳米医学是一种纳米医学.
背景情况:
- 固体瘤是一个重大的全球健康挑战,由于人口老龄化,其发病率越来越高.
- 瘤进展涉及癌细胞和瘤微环境 (TME) 之间的复杂相互作用.
- 免疫检查点抑制剂 (ICI),针对PD-1/PD-L1等途径,增强抗瘤免疫力,但面临显著的耐药性.
研究的目的:
- 审查目前对ICI治疗的固体瘤中药物耐药性机制的理解.
- 探索新的治疗策略,包括组合疗法和纳米医学,以克服ICI耐药性.
- 确定未来的研究方向,以提高ICI在固体瘤中的疗效.
主要方法:
- 关于固体瘤免疫学和治疗的最新进展的综合文献综述.
- 对免疫检查点抑制剂治疗的耐药性背后机制的分析.
- 评估新兴的治疗方式,包括组合疗法和纳米尺度药物输送系统.
主要成果:
- 耐药性是限制免疫检查点抑制剂临床成功的主要障碍.
- 组合疗法和先进的药物输送平台在克服耐药性方面显示出有前途.
- 调节瘤微环境 (TME) 对于提高治疗反应至关重要.
结论:
- 了解抵抗机制是开发更有效的固体瘤治疗方法的关键.
- 结合疗法和纳米医学等创新策略为改善ICI疗效提供了新的途径.
- 未来的研究应该专注于改进这些方法并探索TME调制以获得更好的患者结果.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
相关概念视频
Tumor Immunotherapy
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
